Skip to content
Kit presale · 10% offPay before Dec 2
anhydrolabs
0
Peptide science

Growth Hormone Secretagogues: GHRH Analogs and GHRPs

A growth hormone secretagogue triggers pituitary GH release. Learn the two receptor classes, GHRH analogs and ghrelin-receptor GHRPs, with sequences.

Published · 9 min read · Anhydrolabs

A growth hormone secretagogue is any compound that causes the anterior pituitary to release growth hormone. Research peptides in this class work through one of two receptors: GHRH analogs such as sermorelin, CJC-1295 and tesamorelin activate the GHRH receptor, and growth hormone-releasing peptides (GHRPs) such as GHRP-6, GHRP-2 and ipamorelin activate the ghrelin receptor, GHS-R1a. The two receptors use different G proteins and second messengers, which is why the classes are studied both separately and side by side.

This primer defines the terms, traces how each class was discovered, lays out the members with their sequences and regulatory status, and compares the two receptor systems.

What the term means

In its broadest sense, "secretagogue" means a substance that causes a cell to secrete something. A growth hormone secretagogue causes somatotrophs, the growth hormone-producing cells of the anterior pituitary, to release growth hormone.

In the endocrinology literature the phrase has a narrower history. It was first used for a group of synthetic compounds, beginning with small peptides in the 1980s, that released growth hormone through a receptor that was then unknown. When that receptor was cloned in 1996, it was named the growth hormone secretagogue receptor, GHS-R. Its natural ligand turned out to be ghrelin. So in older papers "GHS" usually means a ghrelin-receptor agonist, and GHRH analogs are discussed separately.

Supplier catalogs and review articles now tend to use the broad sense, covering both receptor classes. This post does the same but keeps the two clearly apart.

Three inputs to the somatotroph

Growth hormone secretion is controlled by at least three hormonal inputs acting on the somatotroph:

InputSourceReceptorEffect on GH release
GHRHHypothalamusGHRH receptor (Gs-coupled)Stimulates
SomatostatinHypothalamusSomatostatin receptorsInhibits
GhrelinMainly stomachGHS-R1a (Gq-coupled)Stimulates

Synthetic secretagogues plug into the two stimulatory inputs. Somatostatin still acts on the same cells: in the 1984 paper that introduced GHRP-6, Bowers and colleagues found that somatostatin-14 and somatostatin-28 both inhibited the growth hormone response to the new hexapeptide.

How each class was found

The two classes were discovered from opposite directions. GHRH was a natural hormone isolated first and then trimmed and modified by chemists. The GHRPs were synthetic compounds first, and their natural counterpart was found fifteen years later.

YearEvent
1982Human GHRH isolated from pancreatic tumors that caused acromegaly; 44-residue sequence reported (Guillemin et al.). GRF(1-29)-NH2 shown to be fully active in vitro (Spiess et al.)
1984His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6) described as a synthetic hexapeptide that releases growth hormone without releasing LH, FSH, TSH or prolactin (Bowers et al.)
1986Plasma DPP-4 shown to inactivate GHRH by removing its N-terminal Tyr-Ala (Frohman et al.)
1996The GHS receptor cloned from pituitary and hypothalamus (Howard et al., Merck)
1998Ipamorelin described as the first selective GHRP-receptor agonist (Raun et al., Novo Nordisk)
1999Ghrelin identified as the natural ligand of GHS-R: a 28-residue peptide with an n-octanoyl group on Ser3 (Kojima et al.)
2005CJC-1295, an albumin-binding GHRH(1-29) analog, described (Jetté et al., ConjuChem)
2010Tesamorelin approved by the FDA as Egrifta
2017Macimorelin approved by the FDA as Macrilen, a diagnostic agent

Class 1: GHRH receptor agonists

These are all built on the N-terminal part of human GHRH, since the first 29 residues carry the activity. They differ in how they deal with DPP-4, which removes Tyr1-Ala2 and destroys activity.

CompoundStructureStabilizing featureStatus
SermorelinGHRH(1-29)-NH2, unmodifiedNoneApproved in the US as Geref; withdrawn 2009 for business reasons
CJC-1295 without DAC (mod GRF 1-29)GHRH(1-29)-NH2 with D-Ala2, Gln8, Ala15, Leu27D-Ala2 resists DPP-4Never approved
CJC-1295 with DACAs above, plus Lys30 carrying a maleimidopropionyl groupD-Ala2 plus covalent binding to albumin Cys34Never approved
TesamorelinGHRH(1-44)-NH2 with trans-3-hexenoyl on Tyr1N-terminal acyl cap blocks DPP-4Approved (Egrifta)

The GHRH receptor (UniProt Q02643) is a 423-residue class B GPCR. UniProt describes it as coupled to G proteins that activate adenylyl cyclase, stimulating somatotroph growth, growth hormone gene transcription and growth hormone secretion. The individual molecules are covered in more depth in Sermorelin vs Ipamorelin, CJC-1295 vs Ipamorelin and our tesamorelin profile.

Class 2: ghrelin receptor agonists

The second class began with Cyril Bowers's work on small synthetic peptides and grew into a family of hexapeptides and pentapeptides, then into non-peptide and peptidomimetic compounds.

CompoundSequence or typeNotes
GHRP-6His-D-Trp-Ala-Trp-D-Phe-Lys-NH2Described in 1984 (Bowers et al.)
GHRP-2 (pralmorelin)D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2Hexapeptide; PubChem lists it as pralmorelin
IpamorelinAib-His-D-2-Nal-D-Phe-Lys-NH2Pentapeptide; derived by removing the central Ala-Trp of GHRP-1
MK-0677Non-peptide small moleculeListed by UniProt among non-peptide GHS-R ligands
MacimorelinPeptidomimetic small moleculeFDA-approved (Macrilen) for the diagnosis of adult growth hormone deficiency
Ghrelin28 residues, n-octanoyl on Ser3The natural ligand

Several patterns run through the synthetic members: D-amino acids, bulky aromatic side chains such as tryptophan and 2-naphthylalanine, a basic lysine near the C-terminus, and a C-terminal amide. Unnatural residues of this kind make short peptides harder for proteases to recognize.

The ghrelin receptor, GHS-R1a (UniProt Q92847), is a 366-residue class A GPCR. UniProt notes that it couples to Gq proteins and mediates production of diacylglycerol and IP3, and that besides ghrelin it binds GHRPs such as GHRP-6 and non-peptide secretagogues such as MK-0677. The receptor is also active in the absence of any ligand, and it is expressed in the pituitary, the hypothalamus and more widely in the brain.

Selectivity within the GHRPs

Not every ghrelin receptor agonist behaves the same way outside the somatotroph. Raun and colleagues compared ipamorelin with GHRP-6 and GHRP-2 in conscious swine in 1998. None of the three changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not raise them above the levels seen after GHRH, even at more than 200 times the level needed for half-maximal growth hormone release. The authors called ipamorelin the first GHRP-receptor agonist with a growth hormone selectivity similar to GHRH's.

For experimental design, that means the choice of GHRP matters. A study that wants to isolate growth hormone release from adrenal-axis responses has reason to prefer ipamorelin; one that is studying those responses has reason to include GHRP-6 or GHRP-2.

The two receptor systems compared

FeatureGHRH receptorGhrelin receptor (GHS-R1a)
UniProt entry (human)Q02643Q92847
Length423 residues366 residues
GPCR familyClass B (secretin family)Class A (rhodopsin family)
Main G proteinGsGq/11
Second messengersCyclic AMPIP3, diacylglycerol, intracellular calcium
Natural ligandGHRH (44 residues)Ghrelin (28 residues, acylated)
Main tissue for GH releasePituitary somatotrophsPituitary somatotrophs and hypothalamus
Research peptidesSermorelin, CJC-1295, tesamorelinGHRP-6, GHRP-2, ipamorelin

Because the two receptors converge on the same cell through different signaling routes, antagonists for each can be used to assign a response to one pathway. Raun's group used exactly that approach to show that ipamorelin acts through the GHRP receptor rather than the GHRH receptor. It is also the reason research catalogs, including ours, list blends that pair one compound from each class.

Downstream: growth hormone and IGF-1

Growth hormone itself acts on receptors in many tissues, and some of its actions are mediated by insulin-like growth factor 1, produced in the liver and in peripheral tissues. Secretagogue studies therefore often measure IGF-1 alongside growth hormone. Engineered IGF-1 analogs act at the very end of the axis; our profile of IGF-1 LR3 covers one of them.

Regulatory status at a glance

CompoundUS regulatory status
SermorelinFormerly approved (Geref); withdrawn effective 2009, not for reasons of safety or effectiveness
TesamorelinApproved as Egrifta (2010) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy
MacimorelinApproved as Macrilen (2017) for the diagnosis of adult growth hormone deficiency
CJC-1295 (either form)Investigational; never approved
IpamorelinInvestigational; a Phase 2 trial in postoperative ileus was completed
GHRP-6, GHRP-2Not approved by the FDA

Research-grade material is a separate matter from any approved product. Anhydrolabs supplies these compounds for laboratory research only, not for human or veterinary diagnosis, treatment, or consumption; the research-use page explains the terms.

Working with secretagogue peptides

The two classes differ in size by almost an order of magnitude, from about 712 g/mol for ipamorelin to about 5,136 g/mol for tesamorelin, so equal mass concentrations give very different molar concentrations. Compare them in molar units. The GHRH-derived peptides mostly carry Met27, which oxidizes to a +16 Da sulfoxide; CJC-1295 replaces it with leucine. The GHRPs are short and contain no methionine or cysteine.

All of these ship as lyophilized powders. Our guides on how to reconstitute peptides and how long peptides last cover preparation and stability, and the storage and handling page lists the conditions we use.

Anhydrolabs supplies ipamorelin, sermorelin, tesamorelin and CJC-1295 (no DAC) as lyophilized powders in vacuum-sealed vials, also available as 10-vial kits.

For laboratory research use only
Every compound discussed here is supplied as a reference material for in-vitro laboratory research. Not for human or veterinary use. Nothing in this article is guidance for use in a person or an animal. See the research-use statement.

Frequently asked questions

What is a growth hormone secretagogue?

A growth hormone secretagogue is a compound that causes the anterior pituitary to release growth hormone. Among peptides, most act either on the GHRH receptor, like sermorelin and tesamorelin, or on the ghrelin receptor, like GHRP-6 and ipamorelin. Historically the term referred mainly to the ghrelin-receptor class.

What is the difference between a GHRH analog and a GHRP?

A GHRH analog is derived from growth hormone-releasing hormone and activates the GHRH receptor, which signals through Gs and cyclic AMP. A GHRP is a synthetic peptide that activates the ghrelin receptor, GHS-R1a, which signals through Gq, phospholipase C and calcium. Both reach the same pituitary somatotrophs.

What is GHS-R1a?

GHS-R1a is the growth hormone secretagogue receptor type 1a, a 366-residue G protein-coupled receptor in humans. It was cloned in 1996 as the target of synthetic secretagogues, and in 1999 ghrelin was identified as its natural ligand. It is now usually called the ghrelin receptor.

Is ipamorelin a growth hormone secretagogue?

Yes. Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that activates the ghrelin receptor. Its 1998 characterization found it released growth hormone without raising ACTH or cortisol above levels seen with GHRH, unlike GHRP-6 and GHRP-2.

Which growth hormone secretagogues are FDA approved?

Tesamorelin is approved as Egrifta, and macimorelin is approved as Macrilen for diagnosing adult growth hormone deficiency. Sermorelin was approved as Geref but withdrawn from the market in 2009 for reasons unrelated to safety or effectiveness. CJC-1295, ipamorelin, GHRP-6 and GHRP-2 are not FDA-approved.

Why are GHRH analogs modified at the N-terminus?

Plasma DPP-4 removes the first two residues of GHRH, Tyr-Ala, leaving a fragment with less than a thousandth of the original activity. Analogs address this in different ways: CJC-1295 uses D-alanine at position 2, and tesamorelin caps the N-terminal amine with a trans-3-hexenoyl group.

References

  • Comparisons

    CJC-1295 vs Ipamorelin, and DAC vs No DAC

    CJC-1295 vs ipamorelin compared: GHRH vs ghrelin receptor, the four substitutions in mod GRF(1-29), and what the Drug Affinity Complex adds.

    · 10 min read

  • Comparisons

    Sermorelin vs Ipamorelin: GHRH vs Ghrelin Pathways

    Sermorelin vs ipamorelin: a GHRH(1-29) analog and a ghrelin-receptor pentapeptide compared by sequence, receptor, signaling and regulatory status.

    · 11 min read

  • Compound profiles

    Tesamorelin: A Stabilized GHRH Analog

    Tesamorelin peptide explained: full-length GHRH(1-44) with a trans-3-hexenoyl cap, why that cap blocks DPP-4, its identity data and FDA status.

    · 9 min read